Stock Scorer

4D Molecular Therapeutics, Inc. (FDMT) · Insider trading

What 4D Molecular Therapeutics's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$5.36M
3 insiders, 100% under a plan
Net, 12 months
−$5.36M
bought less sold
Latest filing
2026-10-07
filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

2025-01 2025-07 2025-09: $19,256 sold 2025-10: $72,844 sold 2025-11: $17,315 sold 2025-12: $21,198 sold 2026-01 2026-03: $3,358 sold 2026-06: $1.43M sold 2026-07: $737,589 sold 2026-07 2026-08: $1.53M sold 2026-09: $841,322 sold 2026-10: $753,937 sold
Bought Sold Largest month: $1.53M

Who traded, two years

InsiderBoughtSold TradesLast tradeHolds after
Kirn DavidDirector, See Remarks – $5.01M 12 2026-10-05 709,425
Bizily ScottChief Legal Officer – $406,941 12 2026-09-16 8,617
Gupta AshooVP, Finance and Controller – $6,734 4 2026-03-20 46,914

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

DateInsiderTradeShares PriceValueHolds afterFiling
2026-10-05 Kirn DavidDirector, See Remarks Saleplan 58,061 12.92 $750,235 709,425 Form 4
2026-10-05 Kirn DavidDirector, See Remarks Saleplan 272 13.61 $3,702 709,153 Form 4
2026-09-16 Bizily ScottChief Legal Officer Saleplan 1,635 13.65 $22,318 8,617 Form 4
2026-09-14 Kirn DavidDirector, See Remarks Saleplan 58,333 13.90 $810,829 767,486 Form 4
2026-09-01 Bizily ScottChief Legal Officer Saleplan 584 14.00 $8,176 8,617 Form 4
2026-08-19 Kirn DavidDirector, See Remarks Saleplan 43,149 15.36 $662,769 851,746 Form 4
2026-08-19 Kirn DavidDirector, See Remarks Saleplan 25,927 16.42 $425,721 825,819 Form 4
2026-08-17 Bizily ScottChief Legal Officer Saleplan 1,635 12.20 $19,947 8,617 Form 4
2026-08-13 Bizily ScottChief Legal Officer Saleplan 1,635 12.00 $19,620 8,617 Form 4
2026-08-04 Kirn DavidDirector, See Remarks Saleplan 26,842 10.23 $274,594 844,895 Form 4
2026-08-03 Kirn DavidDirector, See Remarks Saleplan 12,415 10.05 $124,771 871,737 Form 4
2026-07-10 Kirn DavidDirector, See Remarks Saleplan 15,283 12.01 $183,549 884,594 Form 4
2026-07-10 Kirn DavidDirector, See Remarks Saleplan 442 12.84 $5,675 884,152 Form 4
2026-07-09 Kirn DavidDirector, See Remarks Saleplan 42,608 12.87 $548,365 899,877 Form 4
2026-06-30 Bizily ScottChief Legal Officer Saleplan 6,566 14.00 $91,924 8,617 Form 4
2026-06-23 Bizily ScottChief Legal Officer Saleplan 9,810 12.00 $117,720 8,617 Form 4
2026-06-22 Kirn DavidDirector, See Remarks Saleplan 114,746 10.47 $1.20M 942,485 Form 4
2026-06-01 Kirn DavidDirector, See Remarks Saleplan 1,922 10.02 $19,258 1,057,231 Form 4
2026-03-20 Gupta AshooVP, Finance and Controller Sale 310 8.61 $2,669 46,914 Form 4
2026-03-20 Gupta AshooVP, Finance and Controller Sale 80 8.61 $689 47,055 Form 4
2025-12-20 Gupta AshooVP, Finance and Controller Sale 310 8.68 $2,691 46,218 Form 4
2025-12-20 Gupta AshooVP, Finance and Controller Sale 79 8.68 $686 46,359 Form 4
2025-12-16 Bizily ScottChief Legal Officer Saleplan 1,635 10.90 $17,822 3,594 Form 4
2025-11-17 Bizily ScottChief Legal Officer Saleplan 1,635 10.59 $17,315 3,594 Form 4
2025-10-24 Bizily ScottChief Legal Officer Saleplan 2,678 12.00 $32,136 3,594 Form 4
2025-10-16 Bizily ScottChief Legal Officer Saleplan 1,635 10.17 $16,628 5,188 Form 4
2025-10-09 Bizily ScottChief Legal Officer Saleplan 2,408 10.00 $24,080 5,188 Form 4
2025-09-23 Bizily ScottChief Legal Officer Saleplan 2,407 8.00 $19,256 7,596 Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

17 × option exercise4 × other
Show them
DateInsiderWhatShares PriceHolds afterFiling
2026-09-16 Bizily ScottChief Legal Officer Option exercise M +1,635 4.14 10,252 Form 4
2026-09-01 Bizily ScottChief Legal Officer Option exercise M +584 6.49 9,201 Form 4
2026-08-19 Kirn DavidDirector, See Remarks Option exercise M +50,000 4.14 894,895 Form 4
2026-08-17 Bizily ScottChief Legal Officer Option exercise M +1,635 4.14 10,252 Form 4
2026-08-13 Bizily ScottChief Legal Officer Option exercise M +1,635 4.14 10,252 Form 4
2026-06-30 Bizily ScottChief Legal Officer Option exercise M +814 4.14 9,431 Form 4
2026-06-30 Bizily ScottChief Legal Officer Option exercise M +5,752 6.49 15,183 Form 4
2026-06-23 Bizily ScottChief Legal Officer Option exercise M +9,810 4.14 18,427 Form 4
2026-03-20 Gupta AshooVP, Finance and Controller Option exercise M +865 – 47,224 Form 4
2026-03-20 Gupta AshooVP, Finance and Controller Option exercise M +221 – 47,135 Form 4
2025-12-20 Gupta AshooVP, Finance and Controller Option exercise M +866 – 46,528 Form 4
2025-12-20 Gupta AshooVP, Finance and Controller Option exercise M +220 – 46,438 Form 4
2025-12-16 Bizily ScottChief Legal Officer Option exercise M +1,635 4.14 5,229 Form 4
2025-12-12 Theuer CharlesDirector Option exercise M +9,333 1.14 41,684 Form 4
2025-11-17 Bizily ScottChief Legal Officer Option exercise M +1,635 4.14 5,229 Form 4
2025-10-24 Bizily ScottChief Legal Officer Option exercise M +1,084 6.49 6,272 Form 4
2025-10-16 Bizily ScottChief Legal Officer Option exercise M +1,635 4.14 6,823 Form 4
2024-12-09 Ra Capital Healthcare Fund LP10% owner Other J −535,000 – 4,563,211 Form 4
2024-11-08 Biotechnology Value Fund L POther Other J −3,062,000 – 830,237 Form 4
2024-11-08 Biotechnology Value Fund L POther Other J −2,378,000 – 662,970 Form 4
2024-11-08 Biotechnology Value Fund L POther Other J −240,000 – 87,911 Form 4

How to read it

Buy, sale
Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan
A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after
The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value
Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

4D Molecular Therapeutics's scores and multiples ›